(Q34915917)

5 August 2017

Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study (English)

1 reference

5 August 2017

1 reference

Bill H Chang

1

0 references

Kirk R Schultz

object named as

Kirk R Schultz

9

0 references

Brian Druker

object named as

Brian J Druker

8

0 references

Stephen P Hunger

4

object named as

Stephen P Hunger

1 reference

5 August 2017

7

Naomi J Winick

1 reference

5 August 2017

Stephanie G Willis

2

1 reference

5 August 2017

Linda Stork

3

1 reference

5 August 2017

William L Carroll

5

1 reference

5 August 2017

Bruce M Camitta

6

1 reference

5 August 2017

language of work or name

English

0 references

publication date

2 February 2012

1 reference

British Journal of Haematology

5 August 2017

1 reference

5 August 2017

157

1 reference

5 August 2017

4

1 reference

5 August 2017

507-510

1 reference

Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia

5 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4290865

Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4290865

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4290865

Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4290865

Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4290865

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4290865

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4290865

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4290865

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia

8 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09039.X

Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09039.X

10.1111/J.1365-2141.2012.09039.X

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference

5 August 2017

1 reference